» Authors » Aida Karachi

Aida Karachi

Explore the profile of Aida Karachi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 639
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Long Y, Tao H, Karachi A, Grippin A, Jin L, Chang Y, et al.
Cancer Res . 2019 Nov; 80(3):499-509. PMID: 31723000
Anti-VEGF therapy prolongs recurrence-free survival in patients with glioblastoma but does not improve overall survival. To address this discrepancy, we investigated immunologic resistance mechanisms to anti-VEGF therapy in glioma models....
12.
Jin L, Tao H, Karachi A, Long Y, Hou A, Na M, et al.
Nat Commun . 2019 Sep; 10(1):4016. PMID: 31488817
Chimeric antigen receptor (CAR) T-cell therapy targeting solid tumors has stagnated as a result of tumor heterogeneity, immunosuppressive microenvironments, and inadequate intratumoral T cell trafficking and persistence. Early (≤3 days)...
13.
Casiraghi F, Todeschini M, Azzollini N, Cravedi P, Cassis P, Solini S, et al.
Transplantation . 2019 Feb; 103(6):1121-1130. PMID: 30801518
Background: Mesenchymal stromal cells (MSCs) have protolerogenic effects in renal transplantation, but they induce long-term regulatory T cells (Treg)-dependent graft acceptance only when infused before transplantation. When given posttransplant, MSCs...
14.
Shi X, Karachi A, Hosseini M, Safari Yazd M, Kamyab H, Ebrahimi M, et al.
Ultrason Sonochem . 2019 Feb; 68:104460. PMID: 30712851
The aim of this study was ultrasound assisted removal of Ceftriaxone sodium (CS) based on CCD model. Using sonochemical synthesized BiWO implanted on graphitic carbon nitride/Multiwall carbon nanotube (g-CN/MWCNT/BiWO). For...
15.
Karachi A, Yang C, Dastmalchi F, Sayour E, Huang J, Azari H, et al.
Neuro Oncol . 2019 Jan; 21(6):730-741. PMID: 30668768
Background: The changes induced in host immunity and the tumor microenvironment by chemotherapy have been shown to impact immunotherapy response in both a positive and a negative fashion. Temozolomide is...
16.
Rahman M, Dastmalchi F, Karachi A, Mitchell D
Oncoimmunology . 2018 Dec; 8(1):e1514921. PMID: 30546954
Controversy surrounds the role of cytomegalovirus (CMV) in glioblastoma (GBM). However, several studies have shown that CMV nucleic acids and proteins are present within GBM tumor tissue. CMV has been...
17.
Sayour E, Grippin A, De Leon G, Stover B, Rahman M, Karachi A, et al.
Nano Lett . 2018 Sep; 18(10):6195-6206. PMID: 30259750
Translation of nanoparticles (NPs) into human clinical trials for patients with refractory cancers has lagged due to unknown biologic reactivities of novel NP designs. To overcome these limitations, simple well-characterized...
18.
Karachi A, Dastmalchi F, Mitchell D, Rahman M
Neuro Oncol . 2018 May; 20(12):1566-1572. PMID: 29733389
Temozolomide is the most widely used chemotherapy for patients with glioblastoma (GBM) despite the fact that approximately half of treated patients have temozolomide resistance and all patients eventually fail therapy....
19.
Mu L, Long Y, Yang C, Jin L, Tao H, Ge H, et al.
Front Mol Neurosci . 2018 Apr; 11:82. PMID: 29643764
Malignant gliomas are heterogeneous brain tumors with the potential for aggressive disease progression, as influenced by suppressive immunoediting. Given the success and enhanced potential of immune-checkpoint inhibitors in immunotherapy, we...
20.
Karachi A, Fazeli M, Karimi M, Geramizadeh B, Moravej A, Ebrahimnezhad S, et al.
Immunol Invest . 2015 Jun; 44(5):427-37. PMID: 26107743
Mesenchymal stem cells (MSCs) can modulate dendritic cells (DCs) activation and induce tolerogenic characteristics in DCs. All mechanisms involved in MSCs-induced tolerogenic DCs are not fully understood. MicroRNAs (miRs) play...